INVO Bioscience Inc Ordinary Shares INVO 深 沪
已收盘 07-26 16:00:00 美东时间
0.82
+0.097
+13.42%
华盛通- 最 高0.8399
- 今 开0.723
- 成交量 5.68万股
- 最 低 0.723
- 昨 收 0.723
- 总市值 204.39万
- 52周最高 6.65
- 市盈率 静 --
- 换手率 2.28%
- 52周最低 0.50
- 委 比 98.43%
- 总股本 249.25万
- 历史最高 246.00
- 量 比 1.38
- 振 幅 16.17%
- 历史最低 0.70
- 每 手 1
- 风险率 0.59%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多EastGroup Properties Announces Second Quarter 2024 Results
Second Quarter 2024 Highlights Net Income Attributable to Common Stockholders of $1.14 Per Diluted Share for Second Quarter 2024 Compared to $0.97 Per Diluted Share for Second Quarter 2023 F...
07-24 04:05
快讯 | invo bioscience：于2024年6月18日，公司收到纳斯达克的通知，告知公司已获得在纳斯达克继续上市的请求。
INVO Bioscience: On June 18, 2024, Co Received Notice From Nasdaq Informing Co ...
06-21 04:22
INVO Bioscience files for $100M mixed shelf
INVO Bioscience (NASDAQ:INVO) on Tuesday filed a prospectus for a mixed securities shelf offering of up to $100M. This prospectus is not an offer to sell these securities. SEC Filing More on INVO BioS...
05-22 04:52
MGNI, VERV and GWAV among pre-market gainers
Gainers: TSR (TSRI) +70% on being acquired by Vienna Parent for $13.40 per share. Pineapple Energy (PEGY) +64%. Crown ElectroKinetics (CRKN) +56%. Greenwave Technology Solutions (NASDAQ:GWAV) +56%. Ji...
05-16 21:25
INVO Bioscience Q1 EPS $(0.42), Sales $1.58M Up From $348.02K YoY
INVO Bioscience (NASDAQ:INVO) reported quarterly losses of $(0.42) per share. The company reported $1.58 million in sales this quarter. This is a 352.84 percent increase over sales of $348.02 thousand the same period
05-16 04:45
Peering Into INVO Bioscience's Recent Short Interest
INVO Bioscience's (NYSE:INVO) short percent of float has risen 39.13% since its...
05-16 04:15
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Aclarion (NASDAQ:ACON) shares moved upwards by 66.7% to $0.48 during T...
04-26 00:31
New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
Upadacitinib demonstrated superiority versus dupilumab in primary endpoint of simultaneous achievement of near complete skin clearance (EASI 90) and no to little itch (WP-NRS 0/1) at Week 16...
04-25 20:00
INVO Bioscience Navigates Lease Assignment and Nasdaq Woes
INVO Bioscience (INVO) just unveiled an announcement. INVO Bioscience, through ...
04-20 05:32
Predictive Oncology, BIMI Holdings, IMAC Holdings among healthcare movers
Gainers: Zhongchao (ZCMD) +47%. Neurometrix (NURO) +19%. Mobile health Network Solutions (MNDR) +17%. IMAC Holdings (BACK) +10%. Predictive Oncology (POAI) +10%. Losers: Sunshine Biopharma (SBFM) -39%...
04-19 22:00
